ACOG - alphacognition.com Debt to Book Capitalization Ratio

Brandmark of alphacognition.com (ACOG)

The market capitalization trend of Alpha Cognition (ACOG) helps assess the development of its strategy to create dementia drugs for the elderly, where the indicator stands at 0.00. The business's current financial health relies on external investments, as a stable profit stream has not yet been established. Growth prospects are based on the successful completion of FDA trials and the protection of copyrights for ALS therapy.

Alpha Cognition Inc. (ACOG) - Debts to Book Value from 11/13/2024 to 10/27/2026

alphacognition.com (ACOG) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Quotes Alpha Cognition Inc.|ACOG - Analyst Consensus Forecast
- market capitalization data:
Market Value Alpha Cognition Inc.|ACOG - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Alpha Cognition|ACOG - Total Stockholders' Equity|Market Capitalization to Book Value Ratio alphacognition.com|ACOG - Company Total Assets
- debt and liquidity data:
Debt to Equity Alpha Cognition|ACOG - Long-Term Debt to Equity|Short-Term Debt to Equity Alpha Cognition Inc.|ACOG - Company Aggregate Indebtedness|Debts to Book Capitalization Alpha Cognition Inc.
Fundamental company analysis:ACOG, Alpha Cognition Corp
Original product of Alpha Cognition Inc.

This indicator measures the company's reliance on borrowed funds relative to its equity value, allowing for an assessment of excessive leverage risk during share buybacks. By analyzing the trend of debt obligations to book capital, an investor can determine the financial stability of Alpha Cognition (ACOG) during the costly clinical trials of cognitive drugs conducted in partnership with medical associations.

Competitors of Alpha Cognition

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|VKTX (Viking Therapeutics) - Debts to Book Capitalization|Debts to Book Capitalization SUPN|Debt to Book Capitalization Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|Debt to Book Capitalization Ratio DNLI (Denali)|Harmony Pharma (HRMY) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Biohaven Corp BHVN|Debts to Book Capitalization Amylyx Pharmaceuticals (AMLX)|TRVI - Debt to Net Assets Ratio|PRAX: Debts to Book Capitalization|Debts to Book Capitalization Anavex|CBLL - Debt to Book Value|Debt to Net Assets Ratio prothena.com|Debts to Book Capitalization ALEC (Alector, Inc.)|Debt to Book Value ANNX (annexonbio.com)|OMER: Debt to Book Capitalization Ratio|Debts to Book Value Neurogene Inc NGNE|Debts to Book Capitalization ACIU|VYGR: Debt to Net Assets|Debt to Book Capitalization Ratio Neumora Therapeutics|scilexholding.com (SCLX) - Debt to Book Value Ratio|TVGN: Debts to Book Capitalization|Debts to Net Assets Cognition Therapeutics Inc. (CGTX)|Debt to Book Value Inhibikase|Debt to Book Capital Cassava Pharma (SAVA)|Debts to Book Capitalization ASRT|Coya Therapeutics Inc - Debts to Net Assets|VTGN (VistaGen Therapeutics Inc) - Debt to Book Capitalization Ratio|OVID: Debts to Book Value|Debt to Book Capitalization Ratio Acumen Pharma|CervoMed Corporation (CRVO) - Debt to Book Value Ratio|ATHE (Alterity Therapeutics Ltd.) - Debts to Book Capitalization|Debts to Book Capitalization Clene Nanomedicine|Debts to Book Capitalization PEPG (PepGen Inc.)|Debt to Book Value JUNS (Jupiter Neurosciences, Inc.)|RLMD: Debt to Book Capitalization Ratio|Debts to Book Value Annovis Bio Corporation ANVS|Debts to Book Capitalization GRCE|AIFF: Debt to Net Assets|Debt to Book Capitalization Ratio anewmeds.com|NeuroSense Therapeutics Ltd. (NRSN) - Debt to Book Value Ratio|Debts to Book Capitalization RVPH (Reviva Pharmaceuticals Holdings)|Debts to Book Value MetaVia, Inc. (MTVA)|Debt to Book Value NRXS|Debts to Book Capitalization HSDT (heliusmedical.com)|Debt to Book Capitalization Ratio Passage Bio|Neuphoria Therapeutics, Inc. - Debt to Net Assets Ratio|NERV (Minerva Neurosciences Corp) - Debt to Book Capitalization Ratio|ATHA - Debts to Book Value|ADXN: Debts to Book Capitalization|ALZN (Alzamend Neuro) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Cyclerion Therapeutics Inc.|Debt to Book Capitalization Ratio PTIX|KTTA - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio cortigent.com (CRGT)|Debts to Book Capitalization Avenue Therapeutics|Debt to Net Assets Ratio brainstorm-cell.com BCLI|Cara Therapeutics - Debts to Book Capitalization|Chromocell Therapeutics Corp (CHRO) - Debts to Book Capitalization|Debt to Book Value eliemtx.com ELYM|Intra-Cellular Therapies, Inc. (ITCI) - Debt to Net Assets Ratio|Debts to Book Capitalization LBPH|Debt to Book Value MRNS|NKGen Biotech - Debt to Book Capitalization Ratio|Debts to Book Value NeuroBo Pharmaceuticals Inc (NRBO)|SAGE (Sage Therapeutics, Inc) - Debts to Book Capitalization|Synaptogenix, Inc - Debt to Net Assets|Trevena, Inc. (TRVN) - Debt to Book Capitalization Ratio|VIGL - Debt to Book Value Ratio|Anew Medical - Debts to Book Capitalization|Debts to Net Assets Cerevel Therapeutics Inc